Chapter 019

Antiarrhythmic Drugs

Frank J. Dowd

GENERAL REFERENCES

  1. Bigger JT, Breithardt G, Brown AM, et al.: The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms, Task Force of the Working Group on Arrhythmias of the European Society of Cardiology, Circulation 84:1831–1851, 1991. PUBMED Abstract
  2. Breithardt G, Borggrefe M, Camm JA, Shenasa M, editors: Antiarrhythmic drugs: Mechanisms of arrhythmic and proarrhythmic actions, New York, 2012, Springer.
  3. Drugs for cardiac arrhythmias, Treatment guidelines, Med Lett Drugs Ther 5:51–58, 2007. PUBMED Abstract
  4. Pamukcu B, Lip GY: Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice, Expert Opin Pharmacother 12:131–140, 2011. PUBMED Abstract
  5. Roden DM: Pharmacology and toxicology of Nav 1.5-class 1 antiarrhythmic drugs, Card electrophysiol Clin 6:695–704, 2014. PUBMED Abstract
  6. Roden DM: Personalized medicine to treat arrhythmias, Curr Opin Pharmacol 15:61–67, 2014. PUBMED Abstract
  7. Saeed W, Kowey PR: Antiarrhythmic drug therapy for atrial fibrillation, Amer Coll Cardiol 32:533–549, 2014. PUBMED Abstract
  8. Shu J, Zhou J, Patel C, Yan GX: Pharmacotherapy of cardiac arrhythmias— basic science for clinicians, Pacing Clin Electrophysiol 32:1456–1465, 2009. PUBMED Abstract
  9. Treatment of atrial fibrillation, Med Lett Drugs Ther 56:1446, 2014. PUBMED Abstract
  10. Vaughan EM, Williams DM: Classification of antidysrhythmic drugs, Pharmacol Ther [B] 1:115–138, 1975. PUBMED Abstract